Maintain controlled inflow and outflow, release visible traction and titrate laser exposure; no gauge, cut rate or memorised dose replaces clinical judgement.
Terminology and draft status
Terminology review is not complete. Selected actual WHO UMD queries and their limits are recorded in terminology.md; they do not approve the whole translation.
01Surgical foundations: history and pressure balance
Pars plana vitrectomy (PPV) separates vitreous cutting/aspiration, illumination and infusion to address selected retinal problems. Endophthalmitis, diabetic tractional detachment, choroidal haemorrhage and panretinal photocoagulation (PRP) have different indications and safety priorities. 13
The original historical sequence names Kasner’s open-sky work in 1961, Machemer’s closed VISC system in 1970 and O’Malley’s 3-port approach. These remain historical teaching attributions with unresolved original dates and priority, not verified personal surgical experience. 13
Separating infusion, illumination and working instruments allows controlled access and fluid management. Loss of infusion or excessive outflow can cause hypotony; neither the number of ports alone nor an unverified fixed pressure guarantees globe stability. 4
The original sequence runs from 17G to 23G, 25G and 27G. Gauge affects access, flow and instrument behaviour, but current model design, wound construction and the task matter more than an absolute “large for complex, small for simple” rule. 13 4
The original claim that PPV accounts for over 80% of retinal operations has no defined place, period or denominator here. It is a teaching estimate, not a current service statistic. 14
02Choose instruments and maintain a useful view
For firm diabetic membranes, consider instrument rigidity, available scissors and forceps, access and the intended dissection. A 27G instrument is not automatically inadequate, nor are all 23G or 25G instruments interchangeable. 4
The original viewing examples are wide-angle BIOM and Resight for peripheral work and contact lenses for macular detail. Choose a view that permits the required manoeuvre; lens magnification, stereopsis and illumination do not establish universal superiority or current product eligibility. 1 4
The original 20,000 cpm example has a device-specific counterpart: the 2022 EVA NEXUS submission describes TDC cutters driven at 10,000 cycles/min, cutting on both strokes. Effective cuts/min and mechanical cycles/min must not be treated as the same measurement. 4
Port geometry, duty cycle, aspiration, distance to the retina and tissue engagement all affect fluid movement and traction. The regulatory submission reports bench testing; it does not prove that high cut rate eliminates traction, creates uniformly laminar flow or prevents retinal tears. 4
Historical 20 G with an approximately 0.9 mm incision often required suturing;23G/25G approximate 0.6/0.5 mm and 27 G 0.4 mm are model-dependent examples. Neither “sutureless” nor small gauge guarantees a sealed wound; assess leakage and suture when indicated. 14 4
| Gauge | Approximate diameter | Technical context | Limits |
|---|---|---|---|
| 20G | 0.9 mm | Historical rigid/high-flow instruments; sutured access | Not a universal obsolete-device rule |
| 23G /25G | 0.6/0.5 mm | Common selected systems | Neither universal indication nor guaranteed sutureless closure |
| 27G | 0.4 mm | Fine access; flexibility depends on model | Complex PDR membranes may need different stiffness/flow |
03Release traction and use dyes deliberately
Core vitrectomy creates working space; posterior vitreous detachment (PVD) induction aims to separate the posterior cortical vitreous. The optic-disc region is a familiar starting reference, but attachment and the safe plane vary; forceful induction can create retinal breaks. 1 2
Peripheral vitreous management and examination under scleral depression help identify residual traction or breaks. The vitreous base is firmly attached; aggressive attempts to remove every fibre can cause injury and are not a required manoeuvre for every macular hole. 1
The original sutureless example uses a 30–45° scleral tunnel. Wound architecture, gauge and actual leakage determine closure; “sutureless” is a design aim, not a reason to leave a leaking wound or to call every straight entry malpractice. 4
Triamcinolone can make residual vitreous visible, brilliant blue G preferentially stains ILM, and trypan blue is useful for epiretinal membrane staining. These agents have different targets and formulations; “safe for every membrane” is not an adequate product description. 1 5
Indocyanine green (ICG) improves contrast but concentration, exposure, illumination and subretinal contact influence toxicity. The original 30-second rule is not a universal validated safety boundary; use the specific intraocular product information and minimize unnecessary exposure. 1 5
Triamcinolone particles can reveal residual vitreous but cannot certify complete PVD or complete removal. The original name Kinalog is retained as an unresolved spelling; choose a suitable sterile preparation and respect its product instructions. 14 1
04Select a tamponade and monitor its consequences
Gas tamponade helps support closure, but the choice depends on the operation and the eye. The original SF6 estimate of 3–4 weeks and C3F8 estimate of up to 2 months are not individual clearance dates; published estimates and actual persistence depend on concentration and fill. 1 3
Gas–fluid interfacial properties, contact and buoyancy contribute to tamponade; describing gases simply as having the highest surface tension is not a sufficient selection rule. Longer-acting tamponade for complex detachments or giant retinal tears is a separate decision from routine macular-hole repair. 1 3
The original comparison of 1000 cSt and 5000 cSt silicone oil concerns viscosity and handling. Higher viscosity may resist emulsification under some conditions, but both grades can emulsify; inflammation, impurities, time and ocular movement also matter. 6
In a randomised trial of 100 patients, both low- and high-viscosity oil groups developed emulsification and the difference was not statistically significant. That does not establish equivalence, validate every 1000/5000 cSt product comparison or mean that all proliferative vitreoretinopathy (PVR) requires one viscosity. 6
Sudden visual loss, a new field defect, severe pain, marked inflammation, pressure rise or suspected infection requires urgent assessment. An eye containing gas must avoid flying, high altitude and nitrous oxide until the gas has completely resolved and the treating team confirms safety. 3 13
05Recognize other vitreoretinal emergencies and their evidence limits
Suspected postoperative endophthalmitis requires urgent sampling and antimicrobial treatment coordinated with vitreoretinal care. Do not delay treatment while applying an oversimplified visual-acuity rule. 7 8
EVS randomised 420 patients with endophthalmitis within 6 weeks of cataract surgery or secondary IOL implantation. Its immediate-PPV benefit concerned the light-perception-only subgroup; “≤ light perception” must not be generalized to no-light-perception eyes or every cause and modern setting. 7
The original intravitreal examples are vancomycin 1.0 mg/0.1 ml and ceftazidime 2.25 mg/0.1 ml. The historical ESCRS document lists ceftazidime 2 mg; these source-specific values are not a dilution recipe, and actual treatment requires a checked current local protocol and appropriate pharmacy preparation. 8
For diabetic tractional retinal detachment (TRD), segmentation and delamination release fibrovascular traction. The original optic-disc entry-plane example is a teaching approach, not proof that adhesions are always weakest or dissection safest there; choose the visible plane and avoid traction on adherent retina. 9
A sudden pressure change, loss of red reflex or suspected suprachoroidal bleeding during surgery requires immediate senior assessment and stabilization. The original “Portwine Blood” or “Hafenschlamm” description is not a diagnostic criterion or an instruction for routine high-pressure drainage. 10
Imaging, extent, apposition of detached choroidal elevations, pressure and retinal involvement guide whether and when drainage is considered. The evidence is dominated by heterogeneous observational reports; neither a single drainage technique nor one timing rule is established for every case. 10
Submacular haemorrhage in neovascular age-related macular degeneration (AMD) can prompt consideration of displacement, tPA and anti-VEGF treatment according to timing and anatomy. The original subretinal-tPA/air-or-gas example is one approach, not a universal treatment for blood beneath the macula. 11
STAR randomised 90 people to surgery or pneumatic displacement with tPA and anti-VEGF in both arms; 78 completed the 3-month endpoint. The adjusted visual-gain difference was 1.9 letters (95% CI −11.0–14.9; p=0.767): surgery was not superior, and equivalence was not established. 11
In PDR, segmentation divides tractional bridges; delamination separates fibrovascular tissue from the retinal surface. The optic disc may offer a useful starting plane, but anatomy and adherence decide the entry point; “always start at the nerve” is not a safety rule for every membrane. 14 1
The original 41 G subretinal tPA needle is a selected submacular-haemorrhage technique, not treatment for every bleed. Urgently assess cause, duration, size and visual potential; neither observation in every case nor one mandatory injection technique follows from blood toxicity. 14 11
06Use PRP for its retinal indication and titrate the actual exposure
Panretinal photocoagulation (PRP) treats selected proliferative diabetic retinopathy by applying retinal laser outside the central macula. It is distinct from glaucoma laser and from macular-hole surgery; integrate it with the retinal diagnosis and the overall treatment plan. 9 12
The original 250 mW and 95 ms “sweet spot”, and the claim that every pulse <50 ms carries high rupture risk, are not universal settings. Wavelength, spot size, lens, pigmentation, pulse pattern, tissue response and the actual laser instructions change the exposure. 12
MAPASS compared 20 ms multispot with 100 ms single-spot PRP in 40 eyes of 24 people and measured pain. A studied short-pulse regimen contradicts a blanket <50 ms prohibition, but this small trial does not validate every short exposure or prove long-term equivalence. 12
The original inferior-quadrant-first and 3/9-o’clock nerve-sparing points are technique-specific teaching claims. Treat the indicated retinal area with attention to anatomy, burns, bleeding and collateral damage; they do not establish guaranteed permanent mydriasis after any burn at those clock positions. 9 12
07Review the indication, manoeuvre and limitation together
Return to the patient’s actual diagnosis, OCT findings, duration, remaining function and priorities. A defensible explanation connects the observed problem to the next action and its limitations; memorized device figures or exam threats do not replace that reasoning. 13
| Disease | Selected management | Key concept | Safety boundary |
|---|---|---|---|
| Endophthalmitis | Urgent sampling/intravitreal treatment and selected PPV | Antibiotics; EVS context | LP subgroup is not NLP/all infection |
| PDR tractional detachment | Selected PPV | Segmentation/delamination | Entry plane depends on the actual membrane |
| Macular hole | Selected PPV/ILM peel/gas | Apposition and closure | Positioning is individual, not universal compulsory posture |
| Suprachoroidal haemorrhage | Stabilise pressure/wounds; selected drainage | Liquefaction; original 1–2 weeks | Neither blind infusion nor an absolute ban on earlier rescue |
| Submacular haemorrhage | Selected tPA/gas/surgery | Original 41 G needle | No universal hours-to-damage threshold or identical intervention |
| Inferior retinal break | Selected buckle/PPV/retinopexy | Chorioretinal adhesion | Laser order does not replace adequate treatment of the actual lesion |
08Distinguish PDT use, authorisation and light precautions
Verteporfin PDT activates a photosensitiser with light to treat selected lesions. Use in chronic central serous chorioretinopathy (CSC, original CCS) is different from a labelled US indication: the inspected US text lists predominantly classic subfoveal CNV due to AMD, pathologic myopia or presumed ocular histoplasmosis, not CSC. The Ohio-Valley association does not itself diagnose histoplasmosis. 15 14
Light precautions depend on the applicable product information: the inspected US label specifies 5 days avoiding direct sun/bright indoor light; EU text specifies 48 hours. The original 10 days is not a universal verified rule. Explain the actual local instructions, protective clothing and eye protection; ordinary ambient indoor light is different from bright direct exposure, and sunscreen alone is not adequate protection. 15 16 14
What are the main learning points?
Maintain controlled inflow and outflow, release visible traction and titrate laser exposure; no gauge, cut rate or memorised dose replaces clinical judgement.
When is assessment urgent?
Sudden visual loss, a new field defect, severe pain, marked inflammation, pressure rise or suspected infection requires urgent assessment. An eye containing gas must avoid flying, high altitude and nitrous oxide until the gas has completely resolved and the treating team confirms safety.
References and access status
- 1AAO — Idiopathic Macular Hole PPP,2025
Historical 192-vitreoretinal-surgery-laser appraisal reused; not new full-source access. Historical Review 015 recorded access reused without a fresh full-source claim: Actual official PDF; selected clinical recommendations/text and extracted tables printed P 243–P 255 read. Not full methodology, figures or every cited paper. Prose/table pneumatic-vitreolysis tension remains in the evidence record.
- 2Duker et al. — IVTS classification,2013; PMID 24053995
Historical 192-vitreoretinal-surgery-laser appraisal reused; not new full-source access. Historical Review 015 recorded access reused without a fresh full-source claim: Complete primary indexed abstract and selected original classification text read; original table 1 printed 2612 rendered and visually checked for units/inequalities. Not complete paper or all figures; table/body boundary wording differs.
- 3RCOphth — intraocular gas/nitrous-oxide safety alert,2018
Historical 192-vitreoretinal-surgery-laser appraisal reused; not new full-source access. Historical Review 015 recorded access reused without a fresh full-source claim: Actual official page, gas table and recommendations read; cited case reports not fully read. No fixed individual clearance date inferred.
- 4FDA — EVA NEXUS K213467,14 June 2022
Historical 192-vitreoretinal-surgery-laser appraisal reused; not new full-source access. Historical Review 015 recorded access reused without a fresh full-source claim: Selected actual regulator letter, device/cutter characteristics and bench-testing passages read. Historical configuration, not current full IFU, clinical superiority or EU authorization; original historical/gauge claims remain unresolved.
- 5DailyMed — TissueBlue current hosted label, version 8/effective 20260417
Historical 192-vitreoretinal-surgery-laser appraisal reused; not new full-source access. Historical Review 015 recorded access reused without a fresh full-source claim: Main indication, administration, warning, adverse-effect, description and mechanism text read. US label, not German information. Structured quantity/date anomalies stay documented; no silent formulation inference.
- 6Ratanapakorn et al. — oil-viscosity randomized trial,2020; PMID 32103882
Historical 192-vitreoretinal-surgery-laser appraisal reused; not new full-source access. Historical Review 015 recorded access reused without a fresh full-source claim: Complete primary indexed abstract read. Exact oil viscosities, outcome denominators and full methods need further access; do not relabel it as every original product comparison.
- 7Endophthalmitis Vitrectomy Study,1995; PMID 7487614
Historical 192-vitreoretinal-surgery-laser appraisal reused; not new full-source access. Historical Review 015 recorded access reused without a fresh full-source claim: Complete primary indexed abstract read; full paper/protocol unread. Historical postoperative-cataract population; not a current universal emergency or dosing algorithm.
- 8ESCRS — endophthalmitis guideline,2013/current linked 2018 file
Historical 192-vitreoretinal-surgery-laser appraisal reused; not new full-source access. Historical Review 015 recorded access reused without a fresh full-source claim: Actual official cover/contents and selected acute-treatment/preparation discussion/table 20 printed 22–23 read as text. Not full guideline or preparation appendix; original ceftazidime 2.25 mg differs from this historical 2 mg source.
- 9Retained original PPV/TRD/PRP teaching lecture
Historical 192-vitreoretinal-surgery-laser appraisal reused; not new full-source access. Historical Review 015 recorded access reused without a fresh full-source claim: Original linked lecture identity retained; video, slides and exact transcript not inspected. Unresolved procedural/anatomical claims are teaching material, not verified recommendations; dedicated cross-page review pending.
- 10Ribeiro et al. — perioperative SCH systematic review,2024; PMID 39169423
Historical 192-vitreoretinal-surgery-laser appraisal reused; not new full-source access. Historical Review 015 recorded access reused without a fresh full-source claim: Complete indexed abstract and selected primary introduction/methods read; full tables/reports unread. Mostly case reports/series; no standardized drainage approach.
- 11Gabrielle et al. — STAR randomized trial,2023; PMID 37088447
Historical 192-vitreoretinal-surgery-laser appraisal reused; not new full-source access. Historical Review 015 recorded access reused without a fresh full-source claim: Complete primary indexed abstract read through NCBI E-utilities; full paper, protocol and supplements unread. Superiority not shown is not equivalence.
- 12Muqit et al. — MAPASS report 2,2010; PMID 20558423
Historical 192-vitreoretinal-surgery-laser appraisal reused; not new full-source access. Historical Review 015 recorded access reused without a fresh full-source claim: Complete primary indexed abstract read; direct main report 403. Pain-focused small trial; indexed reversed-order confidence interval not silently repaired or reused.
- 13Own immutable original export: review 192
Historical 192-vitreoretinal-surgery-laser appraisal reused; not new full-source access. Own full clinical export read 17 November 2026; recording and attribution unverified.
- 14Immutable original export; own vitreoretinal/laser teaching; examiner role unverified
Complete export read; original attribution and any recording/transcript or appointment not independently verified.
- 15DailyMed VISUDYNE US prescribing information, revised July 2021; selected indications and photosensitivity text
Official indexed indications and 5-day bright-light precautions read 17 November 2026; not complete prescribing information or German label.
- 16EMA Visudyne product information, sections 4.1/4.4 and official EPAR indication
Selected official indexed indications/photosensitivity 48 hours text and EPAR indication read 17 November 2026; remaining full label and local instructions not appraised.
Original lecture link
For patients
Vitreoretinal surgery treats selected problems inside the back of the eye; the procedure depends on the diagnosis.
Examination and selected imaging guide individual treatment; this teaching text does not replace assessment by your ophthalmologist.
Sudden visual loss, a new field defect, severe pain, marked inflammation, pressure rise or suspected infection requires urgent assessment. An eye containing gas must avoid flying, high altitude and nitrous oxide until the gas has completely resolved and the treating team confirms safety.
Sudden visual loss, a new field defect, severe pain, marked inflammation, pressure rise or suspected infection requires urgent assessment. An eye containing gas must avoid flying, high altitude and nitrous oxide until the gas has completely resolved and the treating team confirms safety.